{"entity":{"id":"bh-501284","kind":"drug","name":"BH-501284","aka":[],"tldr":"BH-501284 is an experimental small molecule from BlossomHill Therapeutics, in preclinical development for solid tumours.","summary":"BH-501284 is a small molecule (oral, non-covalent) from BlossomHill Therapeutics. An orally available pan-KRAS inhibitor on a non-covalent Switch-II scaffold, designed for prolonged, selective inhibition of mutant KRAS while sparing HRAS and NRAS. Its furthest stage is preclinical development, for solid tumours (KRAS-mutant). No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline shows IND-enabling. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"BlossomHill Therapeutics: bhtherapeutics.com","url":"https://www.bhtherapeutics.com/pipeline"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["kras"],"drugs":[],"companies":["blossomhill-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"BH-501284","modality":"Small molecule (oral, non-covalent)","mechanism":"An orally available pan-KRAS inhibitor on a non-covalent Switch-II scaffold, designed for prolonged, selective inhibition of mutant KRAS while sparing HRAS and NRAS.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bh-501284/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"company":[{"id":"blossomhill-therapeutics","kind":"company","name":"BlossomHill Therapeutics","route":"/companies/blossomhill-therapeutics/"}]}}